Last reviewed: June 21, 2026

Last updated: June 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

GLP-1 medications like semaglutide have transformed weight loss treatment, with clinical trials showing average weight reductions of 15% or more. However, people living with heart failure or at risk for heart disease often wonder whether semaglutide is safe for them. Understanding how semaglutide interacts with cardiac health is essential before starting therapy.

How Semaglutide Affects the Heart

Semaglutide activates GLP-1 receptors throughout the body, triggering weight loss and improving blood sugar control. Research indicates that GLP-1 medications may provide direct heart-protective benefits beyond weight reduction. Studies have found that semaglutide can lower blood pressure, reduce inflammation markers, and improve heart function in some patients.

The SUSTAIN-6 trial, which tracked over 3,000 people with type 2 diabetes, demonstrated that semaglutide reduced major adverse cardiovascular events by 26% compared to placebo. This suggests that for many patients, semaglutide offers cardiac protection alongside weight management. However, individual responses vary based on genetics, existing conditions, and medication interactions.

Heart Failure Risk: What the Evidence Shows

Heart failure occurs when the heart cannot pump blood efficiently, and it comes in two main types: reduced ejection fraction (systolic) and preserved ejection fraction (diastolic). Some GLP-1 medications have been studied differently in these populations, and early data suggests outcomes vary. The SGLT2 inhibitors (a different drug class) have shown clear heart failure benefits, while GLP-1 data continues to evolve.

A 2023 analysis of semaglutide clinical trials found no significant increase in heart failure hospitalizations in the overall study population. However, patients with pre-existing heart failure or certain cardiac conditions may experience fluid retention or other changes requiring close monitoring. This underscores why personalized medical assessment—not generic dosing protocols—matters for cardiac patients.

Personalized Screening and Monitoring With PlexusDx

PlexusDx does not recommend semaglutide based solely on weight or age. Instead, a thorough health intake process evaluates your complete medical history, current medications, and cardiac status before therapy begins. Patients with a history of heart failure receive enhanced monitoring protocols and may benefit from alternative formulations or adjunctive therapies.

PlexusDx offers the Precision Peptide Genetic Test, which analyzes key variants in pathways affecting peptide metabolism and cardiovascular response. Genetic markers like GLP1R rs6923761 and MC4R rs17782313 influence how your body responds to GLP-1 therapy. Understanding your genetic profile helps clinicians tailor dose escalation, formulation choice (injection vs. oral), and monitoring intensity to reduce unwanted cardiac effects.

When Semaglutide May Not Be the Right Choice

Semaglutide is not suitable for everyone with heart failure. Patients with severe systolic heart failure (ejection fraction below 30%), recent heart failure hospitalization, or unstable cardiac status should explore alternatives with their cardiologist before starting any GLP-1. Certain medications—such as some blood pressure drugs—can interact with semaglutide, requiring dose adjustments or medication changes.

PlexusDx offers several options for patients unable to safely use standard semaglutide. The Microdose GLP-1 Protocol ($129/mo) uses lower starting doses suitable for cardiac-sensitive patients. Compounded Tirzepatide Injection or GLP-Squared formulations may provide benefits with different safety profiles. Each option is selected based on your unique medical picture, not a one-size-fits-all algorithm.

Managing Fluid Retention and Other Cardiac Symptoms

Some patients on GLP-1 medications report mild fluid retention, swelling in the legs or feet, or changes in blood pressure. These symptoms require immediate communication with your healthcare provider, as they may signal early heart strain. PlexusDx clinicians educate patients on red flags: sudden weight gain (more than 2–3 pounds per day), shortness of breath, or chest discomfort.

Monitoring frequency increases for cardiac patients on semaglutide—typically check-ins every 2 weeks initially, then monthly once stable. Blood pressure checks, weight trends, and symptom assessments guide dose decisions. If side effects emerge, PlexusDx can pause therapy, reduce dose, switch formulations, or recommend alternative compounds without penalty or price changes.

Cost and Access for Cardiac Patients

PlexusDx Compounded Semaglutide Injection starts at $149 per month across all commitment tiers, with no dose-related price increases—whether you require a 0.25 mg or 2.4 mg dose. This transparent pricing removes barriers for cardiac patients who may need careful dose escalation and extended monitoring. The medication is dispensed from licensed 503A compounding pharmacies serving all 50 states, with no insurance requirement or membership fee.

Patients can apply HSA or FSA funds toward semaglutide and the optional Precision Peptide Genetic Test ($99 add-on after the first month). This flexibility helps cardiac patients access personalized therapy without unexpected out-of-pocket costs. For those who prefer oral formulations, PlexusDx offers Oral Semaglutide starting at $249/mo—ideal for patients who cannot tolerate injections.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is semaglutide safe if I have heart failure?

Safety depends on your heart failure type, severity, and current medications. SUSTAIN-6 and other trials show cardiovascular benefits in many patients, but those with unstable or severe heart failure require cardiologist approval and intensive monitoring. PlexusDx conducts a detailed health screening and may recommend lower-dose protocols, alternative compounds, or continued observation before starting therapy.

What do clinical trials say about GLP-1 medications and heart failure risk?

SUSTAIN-6 demonstrated that semaglutide reduced major adverse cardiovascular events by 26%, with no overall increase in heart failure hospitalizations. However, some subgroups—particularly those with pre-existing reduced ejection fraction—showed mixed outcomes. Ongoing trials continue to clarify risk in specific cardiac populations, and PlexusDx monitors emerging evidence to adjust protocols.

How much does semaglutide cost, and will my price increase as my dose goes up?

PlexusDx Compounded Semaglutide Injection starts at $149/mo and remains at that price regardless of dose escalation—your dose may need to go up, but your price won't. This flat pricing applies across all three commitment tiers, and the medication is HSA/FSA eligible with no insurance required.

What symptoms should I watch for if I have heart failure and take semaglutide?

Report sudden weight gain (more than 2–3 pounds per day), shortness of breath, chest discomfort, or leg swelling to your PlexusDx clinician immediately. Fluid retention and blood pressure changes can occur and require prompt evaluation. PlexusDx provides enhanced monitoring for cardiac patients and adjusts or pauses therapy if adverse signs emerge.

How can genetic testing help me if I have heart failure and want to try GLP-1?

The PlexusDx Precision Peptide Genetic Test analyzes key variants like GLP1R rs6923761 and MC4R rs17782313 that influence your cardiovascular response to GLP-1 therapy. This helps clinicians predict which compound, dose, and monitoring schedule best suit your genetic profile and cardiac history, reducing trial-and-error adjustments.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves